Abstract:
The aim of this study is to find the impact of calcium-vitamin D supplement on the dissolution profile of Rocovus® (rosuvastatin calcium). Rosuvastatin is a cholesterol lowering drug and is
used in hyperlipidemia and dyslipidemia. On the other hand, calcium-vitamin D supplements are
used in patients who lack in calcium and vitamin D. Dissolution test of these two agents are
performed to observe if there is any change in their release pattern when they are combined than
they are dissolved individually. The test is performed under optimum conditions. The dissolution
test was performed by using distilled water (as dissolution medium) with USP dissolution
apparatus II. The dissolution tester was run in 37°C temperature at 50 rpm for 60 minutes. The
absorbance of the samples were measured by UV-spectrophotometer at 241 nm. A standard
curve equation of Rosuvastatin was established for the calculation of percent dissolved amount of drug. The dissolution of individual Rocovus® tablets and also combination with the Calcium
and Vitamin D supplement drugs were determined after 10, 20, 30, 40, 50, 60 minutes. Six samples of each individual Rocovus® tablets and combination with the Calcium and Vitamin D
supplement drugs were subjected to determine the dissolution profile. It was observed that at 10
minutes the average percent of drug release was 40.74% that create an impact of 24.36%. After
60 minutes the average percent of drug release was 50.03% and the impact of dissolution altered
was 29.90%. So, it was clear that with increasing time the dissolution or the drug release of Rocovus® is decreased when it is combined with calcium and vitamin D supplement. The reason
for such decrease in drug release is due to common ion effect. Finally, it can be concluded that
rosuvastatin should not be co-administered with calcium-vitamin D supplement.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.